|Day Low/High||1.99 / 2.06|
|52 Wk Low/High||1.81 / 3.15|
Conference Call Scheduled for 8:00 a.m. ET on Tuesday, August 1
Investors eyeing a purchase of Geron Corp. stock, but tentative about paying the going market price of $2.96/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Investors in Geron Corp. saw new options become available this week, for the December 15th expiration.
OncoMed Pharmaceuticals, Geron and Akorn were among the biotech stock movers in premarket trading on Monday.
Innoviva, Akebia Therapeutics and Geron were among the biotech stock movers in premarket trading on Tuesday.
Conference Call Scheduled for 4:30 p.m. ET Today, March 1
Investors in Geron Corp. saw new options become available this week, for the September 15th expiration.
Gilead Sciences is nearing the completion of two phase III studies of the Jak inhibitor momelotinib in myelofibrosis, a disease affecting bone marrow.
Conference Call Scheduled for 4:30 p.m. EDT Today, November 3
Geron (GERN) announced on Monday that it agreed to a licensing deal with Janssen Pharmaceuticals worth $80 million.
Conference Call Scheduled for 8:00 a.m. EDT Today, September 12
Conference Call Scheduled for 4:30 p.m. EDT Today, August 3
Trade-Ideas LLC identified Geron (GERN) as a strong on high relative volume candidate